Benkö Tamas, Hoyer Dieter P, Saner Fuat H, Treckmann Jürgen W, Paul Andreas, Radunz Sonia
Department of General, Visceral and Transplantation Surgery, University Hospital of Essen, University Duisburg-Essen, Essen, Germany.
Transplant Direct. 2017 Oct 18;3(11):e224. doi: 10.1097/TXD.0000000000000738. eCollection 2017 Nov.
The demand for transplantable organs exceeds donor organ supply. Transplantation of organs from donors with a history of malignancy remains controversial and the transmission of cancer in liver transplant recipients has not been sufficiently examined.
From 2002 until 2017, 83 livers from donors with a history of malignancy were transplanted at the University Hospital Essen, Germany. Donor and recipient data, type of malignancy, tumor-free interval at organ procurement, and follow-up data were analyzed.
Nine different tumor sites (central nervous system [n = 27], genitourinary [n = 24], breast [n = 10], skin [n = 8], colorectal [n = 5], lung [n = 3], hemato-oncological [n = 3], thyroid [n = 2], and larynx [n = 1]) were detected in 83 donors. The majority (58%) of donors had tumor-free intervals of less than 5 years versus 19% of 6 to 10 years versus 23% over 10 years. The risk of tumor transmission from donors was assessed as low in 44 (53%), intermediate in 28 (34%), and high in 11 (13%) cases. During median follow-up of 19.9 (0-155) months, none of the recipients developed donor-transmitted malignancy.
Liver transplantation with organs from donors with a medical history of malignancy is feasible, and the risk of donor-transmitted malignancy appears to be low in this single-center analysis. A careful selection of donors remains mandatory and can expand the donor pool.
可移植器官的需求超过了供体器官的供应。来自有恶性肿瘤病史供体的器官移植仍存在争议,且肝移植受者中癌症的传播尚未得到充分研究。
2002年至2017年期间,德国埃森大学医院对83例有恶性肿瘤病史供体的肝脏进行了移植。分析了供体和受体数据、恶性肿瘤类型、器官获取时的无瘤间隔以及随访数据。
在83例供体中检测到9个不同的肿瘤部位(中枢神经系统[n = 27]、泌尿生殖系统[n = 24]、乳腺[n = 10]、皮肤[n = 8]、结直肠[n = 5]、肺[n = 3]、血液肿瘤学[n = 3]、甲状腺[n = 2]和喉[n = 1])。大多数(58%)供体的无瘤间隔小于5年,19%为6至10年,23%超过10年。44例(53%)供体肿瘤传播风险评估为低,28例(34%)为中等,11例(13%)为高。在中位随访19.9(0至155)个月期间,没有受者发生供体传播的恶性肿瘤。
在这项单中心分析中,使用有恶性肿瘤病史供体的器官进行肝移植是可行的,且供体传播恶性肿瘤的风险似乎较低。仔细选择供体仍然是必要的,这可以扩大供体库。